To validate the hypothesis, the CR-NSCLC cells were subjected to miR-556-5p knockdown (KD-miR-556-5p), NLRP3 downregulation (KD-NLRP3) and pyroptosis inhibitor NSA, and the cells were divided into five groups as follows: Control, cisplatin alone, cisplatin + KD-miR-556-5p, cisplatin + KD-miR-556-5p + KD-NLRP3, and cisplatin + KD-miR-556-5p + NSA. Here, NLRP3 is linked to non-small cell lung carcinoma.